Atezolizumab is approved by FDA for alveolar soft tissue sarcoma

Share This Post

Dec 2022: Atezolizumab (Tecentriq, Genentech, Inc.) has been approved by the Food and Drug Administration (FDA) for adult and paediatric patients with unresectable or metastatic alveolar soft part sarcoma who are 2 years of age or older (ASPS).

In Study ML39345 (NCT03141684), an open-label, single-arm study involving 49 adult and paediatric patients with metastatic or unresectable ASPS, efficacy was assessed. A ECOG performance status of 2 and histologically or cytologically proven ASPS incurable by surgery were prerequisites for eligibility. Patients were disqualified if they had primary central nervous system (CNS) cancer or symptomatic CNS metastases, clinically significant liver illness, a history of organising pneumonia, pneumonitis, or active pneumonitis on imaging. Pediatric patients got 15 mg/kg (up to a maximum of 1200 mg) intravenously once every 21 days until illness progression or intolerable toxicity. Adult patients received 1200 mg intravenously.

Overall response rate (ORR) and duration of response (DOR), which were determined by an independent review committee using RECIST v1.1, were the primary efficacy outcome measures. (95% CI: 13, 39), ORR was 24%. Sixty-seven percent of the 12 patients who had an objective response had a DOR of six months or longer, and 42 percent had a DOR of twelve months or longer.

The median patient age was 31 years (the range was 12-70); there were 47 adult patients (2% of them were over 65 years old) and 2 paediatric patients (aged 12); 51% of the patients were female; 55% were White; 29% were Black or African Americans; and 10% were Asian.

The most frequent adverse reactions (15%) were musculoskeletal pain (67%), fatigue (55%), rash, cough, nausea, headache, and hypertension (43% each), constipation, dyspnea, dizziness, and haemorrhage (29% each), decreased appetite and arrhythmia (22% each), influenza-like illness, weight loss, and allergic rhinitis anaphylaxis (18% each).

Adult patients should take atezolizumab at a dosage of 840 mg every two weeks, 1200 mg every three weeks, or 1680 mg every four weeks until their disease progresses or the side effects become intolerable. Children 2 years of age and older should get 15 mg/kg (up to 1200 mg) every 3 weeks until the condition progresses or there is intolerable toxicity.

View full prescribing information for Tecentriq.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy